The Lancet Oncology in conversation with

Iberdomide, daratumumab, and dexamethasone as a treatment option for patients with relapsed or refractory multiple myeloma.

Click here the full article:

S1470-2045(26)00450-X

In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Belfast, UK) to discuss the outcomes and implications of the latest Lancet Oncology Commission on cccelerating equitable cancer genomics and precision oncology in health care and research.

Explore the Commission and related content:

https://www.thelancet.com/commissions-do/accelerating-equitable-cancer-genomics

Look at the infographic:

https://www.thelancet.com/infographics-do/universal-access-precision-oncology

Read the full Commission:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5

Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology.

To read the publications discussed, see: 

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6
 
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0

5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer.

Click here to read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext

Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma.

Click here to read the full article: 

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext